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Abstract 
 
Objectives: Across diagnosis groups, successful transition of adolescent and young adults 
from children’s hospitals to adult care is often associated with decreased treatment adherence 
and treatment results. The aim of this study was to characterize disease activity and anti-
rheumatic medications following transfer of care of juvenile idiopathic arthritis (JIA) patients 
to the adult clinic. 
  
Method: All consecutive JIA patients aged 16 to 20 years who visited the specific transition 
clinic in the rheumatology outpatient clinic of Helsinki University Hospital between 
November 2012 and May 2013 and between April 2015 and April 2016 were evaluated. 
  
Results: A total of 214 patients were identified, and 23 appeared in both cohorts. Females had 
higher disease activity scores than males (DAS28 1.9±0.7 vs. 1.6±0.3, P=0.019; and DAS44 
1.0±0.7 vs. 0.7±0.5, P=0.005; respectively) in the latter cohort. Disease-modifying 
antirheumatic drugs (DMARDs) were prescribed to 86% of patients, and 48% were on 
biological DMARDs (bDMARDs), whereas 14% had no specific treatments. 
 
Conclusions: Disease activity and clinic attendance remained stable during the transition 
period. The proportion of transition phase JIA patients on bDMARDs was high and disease 
activity was low. Reasons for lower disease activity in males in the latter cohort require 
further investigation.  
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Introduction 
 
Juvenile idiopathic arthritis (JIA) is a group of arthritides that emerge before the age of 16 (1). 
The incidence of JIA in the Nordic countries is 15-19.5/100 000 (2). The course of disease 
varies from self-limiting monoarthritis to chronic destructive forms of polyarthritis (3). Up to 
50% of JIA patients were not in remission eight years after diagnosis in a Nordic population-
based study (4), and radiological joint damage may be as common as in adult onset 
rheumatoid arthritis (5). Although the prognosis of JIA has improved in the past decades (6), 
transition from pediatric care to an adult clinic is a challenging time period for maintaining a 
good doctor-patient relationship as well as continuity of treatments and satisfactory disease 
control. Transitional care programs have been developed to meet the special needs of 
adolescent patients (7-10), and recommendations for the transition of care of young people 
with JIA have been published recently (11). However, evidence on the outcome and 
medications of transition phase (16-24 years) patients are still limited.  
The transition process spans several years and is composed of three phases: I) preparation of 
the patient and family for the transfer of care from pediatricians to adult specialists, II) actual 
transfer of care with close collaboration of specialists involved in patient care, and finally, III) 
follow-up at the adult clinic (7). During the third phase, patients still require special attention 
from service providers due to the patients’ young age, gradually increasing autonomy and 
great differences in maturation between individuals. The last phase of transition has, however, 
often been the “weakest link” for many different diagnosis groups. 
To assess treatment protocols and results after the establishment of a transition clinic in adult 
rheumatology, we investigated the disease activity and medications of transition phase JIA 
patients at the Helsinki University Hospital (HUH) adult rheumatology clinic. We 
hypothesized that treatment results would gradually improve after the establishment of a 
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transition clinic in adult services and that close collaboration with pediatricians would 
decrease the need for changes in medication after the transfer of care. 
 
 
Materials and Methods 
 
Transition process development 
The HUH rheumatology outpatient transition clinic was instituted in 2011. Transition phase 
patients visit the clinic on Tuesdays and one adult rheumatologist and one nurse are 
responsible for their care. Transitional patients visit the clinic usually every 6-9 months, and 
visits at the transition clinic usually continue up to the age of 20 years. Thereafter follow-up 
depends on the patients’ clinical status and ongoing medications. Patients on disease-
modifying antirheumatic drugs (DMARD) are usually followed by adult rheumatologists 
either at HUH or local hospitals, whereas patients with inactive disease are referred to general 
practitioners. Before the launch of a transition clinic, transition phase patients had no 
particular doctor or nurse appointed to them. 
 
Patient cohort  
Practically all JIA patients who require follow up after treatment by specialists in pediatric 
rheumatology in Southern Finland are referred to the HUH rheumatology outpatient transition 
clinic, which has a background population of 1.6 million. Transition of rheumatology patients 
from pediatric to adult specialists occurs based on individual assessment at the age of 16-18 
years. Since public health care in Finland is based on national social security, insurance type 
or coverage is irrelevant. 
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Using the patient registry of our hospital, we identified two diagnosis groups (ICD-10 codes 
M08.0-M08.9 and M09.0*L40.5) that included all of the JIA patients aged 16 to 20 years who 
visited the HUH rheumatology outpatient transition clinic. To compare cohort effects, we 
gathered data on patients who attended the transition clinic between November 2012 and May 
2013 (Cohort 2013) and between April 2015 and April 2016 (Cohort 2015).  
 
 
Clinical data 
We conducted a meticulous review of patient records and collected data on previous and 
ongoing medications. Disease outcome was evaluated by the health assessment questionnaire 
disability index (HAQ) (12) and disease activity scores (DAS) 28 (13, 14) and DAS44 (15, 
16). The DAS-CRP is a modification of the DAS28. Originally the DAS28 includes the 
measured erythrocyte sedimentation rate (ESR) value, while the DAS-CRP uses the serum C-
Reactive Protein (CRP) instead. In this study, DAS28 refers to DAS-CRP. Bath ankylosing 
spondylitis disease activity index (BASDAI) (17) was used in patients with enthesitis related 
arthritis (ERA) (ICD-10 code M08.1).   
 
The HAQ assesses the patient’s ability to perform 20 activities of daily living with four 
response options (from “without any difficulty” to “not able to do”; respective scores ranging 
from 0 to 3). These activities are classified into eight categories, and the category score is the 
highest score of any activity within the category. The total HAQ score is the mean of the 
category scores. HAQ was not routinely collected at our center in 2013 and could only be 
analyzed in the 2015 cohort. Because ankle affection is a common feature in JIA, DAS44 
which includes also joints distal to the knees, was used in addition to DAS28. Remission was 
defined as DAS28 <2.6 (14) and DAS44 <1.6 (18). Juvenile arthritis DAS or other pediatric 
6 
 
measures were not included. Longitudinal data was obtained for 23 patients who were present 
in both cohorts.  
 
Ethics 
Data were collected retrospectively from patient records. Thus approval by the ethics 
committee was not required for this study at our center. 
 
Statistical methods 
Data are presented as mean ± standard deviation (SD) for continuous variables, or in case of 
skewed distribution, median with range. For categorical variables, percentages are reported. 
T-tests were used for comparisons between normally distributed continuous variables. 
Nonparametric tests were used when distributions were skewed and with nominal values. A p-
value <0.05 was considered statistically significant. Data analyses were performed using IBM 
SPSS Statistics 22 (IBM, Somers, NY). 
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Results 
 
A total of 214 patients were identified and 23 of them were present in both cohorts. The 
cohorts were similar in regard to age, gender distribution, and duration of the disease (Table 
1). Disease duration ranged from one to 18 years. Three patients also had diabetes mellitus 
and two Down’s syndrome. The majority of patients had juvenile oligoarthritis or 
polyarthritis, and 7-8% were rheumatoid factor (RF) positive (Table 1). One patient had 
arthritis associated with colitis ulcerosa. In the rest arthritis was unclassified. A quarter of the 
patients had a history of uveitis, and the presence of positive antinuclear antibodies (ANA) 
correlated with uveitis (p<0.001). The proportion of HLAB27 positive patients was high 
especially in the 2013 cohort. Clinical data are presented in Table 2. Up to 17% of patients in 
the 2013 cohort smoked at least occasionally, whereas only 6% of the patients in the 2015 
cohort were smokers (P=0.002). The no show rate was 11% in both cohorts, and these patients 
were instructed to contact the outpatient clinic for a new appointment.  
 
Disease activity 
In the whole study population, disease activity was low, and only three patients had 
undergone surgery for rheumatic manifestations. Median HAQ was 0 (range 0-1.5). 
According to both DAS28 and DAS44 remission criteria, 89% of patients were in remission. 
Disease activity parameters according to gender are presented in Table 2 for both cohorts. 
DAS28 was 1.8±0.7 and DAS44 was 0.9±0.6 in JIA patients other than ERA. The BASDAI 
of ERA patients was low in the whole population (median 1.3, range 0-8.2). HAQ and DAS28 
were similar in RF-positive and RF-negative patients. The HLAB27 status showed no 
association with disease activity parameters or treatment regimens. 
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Medication during the transition phase 
In the 2013 cohort, 83% of the patients used antirheumatic medication. Almost half (48%) 
used biological DMARDs (bDMARDs), while 39% used a combination of synthetic 
DMARDs and bDMARDs, and 9% were on bDMARD monotherapy. The most commonly 
used synthetic DMARDs were methotrexate (MTX, 54%), hydroxychloroquine (12%) and 
sulfasalazine (11%). Only 4% of patients used oral glucocorticoids, and 12.5% received intra-
articular injections at the clinic. In general, antirheumatic medication remained the same in 
the 2015 cohort (Table 2) but some changes occurred in the use of bDMARDs over time 
(Table 3). Compared to the medication at the last appointment at the children’s hospital, 57% 
of patients on bDMARDs continued using the same bDMARD, 22% had started a bDMARD, 
13% had switched the bDMARD, and 9% had stopped using bDMARDs. All medications 
were discontinued from 10% of patients who had DMARD treatments at their last visit at the 
children’s hospital. No significant differences were found between the 2013 and 2015 cohorts. 
In the 2015 cohort, etanercept was the most common first bDMARD (49%) followed by 
adalimumab, golimumab, and infliximab (17% each) whereas adalimumab was the most 
common second-line bDMARD and golimumab the most common third-line bDMARD. 
 
All patients with seropositive JIA were females, and the onset of the disease was at an older 
age (Table 4). In the 2013 cohort, RF positive patients were more often on bDMARDs than 
RF negative patients (88% vs. 45%, P=0.02), but their use of synthetic drugs was similar. 
 
Twenty-three patients were present in both cohorts. Their clinical status remained stable 
during follow-up (Table 5). Nine patients underwent changes to their bDMARD treatment. 
Four patients’ bDMARD was terminated, two due to a side-effect and two because of long-
standing remission. In three cases bDMARD was switched to another product due to 
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insufficient efficacy, and two patients’ commenced bDMARD treatment during the follow-up 
period. 
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Discussion 
 
In this retrospective study, transition phase JIA patients had both low disease activity and a 
low degree of disability, and treatment results remained stable between two study cohorts. 
Patients commonly received highly individualized bDMARD-based treatment. 
 
Treatment of adolescents with chronic diseases is challenging. Special transition outpatient 
clinics have been instituted in many rheumatology clinics to provide better transitional care 
for adolescents, but a need for improving transition care remains (19). At HUH, one 
rheumatologist and one nurse are available for transition stage patients at the adult clinic once 
a week. Treatment and appointments can be tailored according to the individual patient’s 
needs, e.g. appointment duration can be one hour instead of the routine 30 minutes if required. 
In addition, patients may contact a rehabilitation counsellor, social worker, physiotherapist or 
occupational therapist, who are also available after the doctor’s appointment.   
 
Our study cohorts represent the local treatment strategies and patient outcomes during the last 
phase of transition since practically all JIA patients with ongoing disease activity from the 
metropolitan Helsinki area enter the HUH transition outpatient clinic at the age of 16 to 18 
years. However, this study cohort does not represent the whole JIA population of the 
respective area because JIA patients without DMARD treatment are commonly transferred to 
general practitioners. The prevalence of HLAB27 in our cohort was higher than that in a 
previous study of JIA patients (20). HLAB27 positive JIA patients with a more severe disease 
may be overrepresented in our study population, since JIA patients with less severe disease 
may have been transferred to other hospitals already by the age of 20 years. In addition, the 
small number of follow-up patients in this retrospective study limits evaluation of disease 
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course during follow-up. In the future, routinely collected quality of life measures will 
provide more information. 
 
According to earlier studies (3, 4), many JIA patients have ongoing disease activity and 
subsequent functional impairment in adulthood. Treatment outcomes with a more recent 
diagnosis, more active treatment and enhanced transition programs, however, seem to have 
improved (21). Up to one-third of patients have reported functional limitations (22) and they 
are at higher risk for unemployment (23). Although JIA and rheumatoid arthritis are different 
diseases, both of them can cause severe joint damage if untreated. High rates of radiographic 
hip damage have been reported in young adults (20-31 years) with polyarticular JIA (5). 
Evidence suggests that active treatment of arthritis is beneficial in JIA (24-26). Strict disease 
control may explain the low degree of functional impairment and disability in the present 
study population. Almost all seropositive patients were on bDMARDs and reported no 
significant functional impairment. The relapse rate after termination of DMARDs is 
substantial in JIA (27). Whether it is possible to taper these medications in early adulthood 
remains to be studied.  
 
Among our patients, disease activity of male patients was lower than that of females 
especially in the latter cohort. Previous studies have shown that the cumulative number of 
affected joints in females with JIA is higher than in males and that HLAB27 predicts a more 
severe disease course (20, 28). Female gender is also associated with more pain and poorer 
function in JIA (29). In our study, females reported more pain although treatment strategies 
were similar between the sexes. Pain alone fails to explain the higher DAS28 and DAS44 in 
females. The cause for lower disease activity in males in the latter cohort remains unknown, 
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but possible explanations may be related to treatment adherence and require further 
investigation.  
Disease activity measured by DAS28 and DAS44 gave similar results, and we found no 
specific indications to use the DAS44 in JIA patients. We found no difference in rates of 
smoking between genders but smoking decreased from cohort 2013 to cohort 2015. This may 
reflect a similar trend as in the general population of young Finns (30).  
 
In a recent cross-sectional study of Finnish adult outpatient rheumatology clinics (31), 21% of 
rheumatoid arthritis patients used bDMARDs, which is clearly less than the proportion of 
transition phase patients using bDMARDs in our study (48%). However, only 52% of adult 
patients were in DAS28 remission compared to 89% of patients in the present study. In 
addition, the median time from diagnosis was shorter in the adult population (7.2 years) than 
among our JIA patients (8.4 years). In another recent study from Tampere, Finland, only 29% 
of adolescent and young adult JIA patients were on bDMARDs and 58% of patients had some 
disease activity within the past year (32). The use of bDMARDs in our cohort is in 
concordance to a French study (33), where up to 50% of transitional JIA patients were on 
bDMARDs. It is possible that adolescents with long life expectancy may be treated more 
actively than adult patients in an attempt to avoid future disability and during a developmental 
stage that possibly increases vulnerability to autoimmunity (34). Golimumab had become the 
most popular bDMARD already in the 2015 cohort although it has only been indicated in the 
treatment of JIA since 2016. According to a Finnish register study (35), only 5.8% of adult 
patients on bDMARDs between 2004 and 2014 used golimumab. Especially for young 
patients, the once in a month dosing regimen of golimumab may often be an attractive 
alternative to the other bDMARDs which require injections every 1-2 weeks and may even 
enhance treatment adherence. 
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In conclusion, high rates of clinic attendance and remission and low disease activity as well as 
a good functional status can be achieved by strict disease control, treatment strategies that are 
attractive to patients and enhanced doctor-patient relationships in transition phase JIA 
patients. Through enhanced care transitions, avoiding future joint damage and functional 
impairment become realistic goals. Prospective studies are still needed to evaluate the long-
term effects of bDMARD treatments on JIA populations reaching adulthood and whether 
successful tapering of DMARDs in adulthood is conceivable. Our study highlights that in the 
treatment of adolescents and young adults, special knowledge, communication skills and 
clinics are required to reach optimal treatment results. 
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Table 1. Clinical characteristics of the study cohorts. 
 Cohort 2013 
(n= 109) 
Cohort 2015 
(n=128) 
 
Age, years  17 (16-20) 17 (16-20)  
Females, n (%) 74 (68) 91 (71)  
Disease duration, years 8.0 (1-18) 7.5 (1-19)  
Time since transfer of care, months 18 (2-56) 18 (2-56)  
RF positive, % 7 8  
ANA positive, % 33 32  
HLAB27 positive, % 43 35  
History of uveitis, % 25 25  
Diagnoses, % 
   Seropositive (M08.0) 
   Enthesitis related arthritis (M08.1) 
   Polyarthritis (M08.3) 
   Oligoarthritis (M08.4) 
   Psoriatic arthritis 
 
7 
12 
33 
39 
6 
 
9 
13 
31 
40 
4 
 
Smoking, n (%)  17 6 P=0.002 
 
Age, disease duration and time since transfer of care presented as median (range). RF, 
rheumatoid factor; ANA, antinuclear antibodies.
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Table 2. Characteristics and disease outcome parameters of females and males with juvenile 
idiopathic arthritis (JIA). 
   Cohort 2013    Cohort 2015  
 Females, n=74 Males, n=35 Females, n=91 Males, n=37 
Height, cm 162±7 179±6** 163±7 176±0** 
Weight, kg 58.3±10.9 68.7±10.0 59.4±10.9 68.6±15.8 
BMI, kg/m2 22.0±4.3 21.6±2.9 22.3±4.5 22.0±3.0 
RF positive, n (%) 7 (9%) 1 (3%) 10 (11%) 0 (0%) 
CRP, mg/l 1 (1-83) 1 (0-100) 1 (1-57) 1 (0-7) 
ESR, mm/h 7 (1-40) 2 (0-54) 7 (2-57) 2 (0-17)** 
Swollen joints 0 (0-9) 0 (0-9) 0 (0-6) 0 (0-4) 
Tender joints 0 (0-11) 0 (0-6) 0 (0-1) 0 (0-4) 
VAS pain, mm 12 (0-88) 8 (0-65) 15 (0-90) 3 (0-65)* 
DAS28 2.1±1.0 2.0±1.0 1.9±0.7 1.6±0.3*, # 
DAS44 1.1±0.9 0.8±0.7 1.0±0.7 0.7±0.5* 
MTX, n (%) 45 (60) 14 (40) 51 (56) 14 (38) 
bDMARD, n (%) 32 (43) 20 (57) 41 (45) 13 (35) 
Smoking, n (%) 12 (16) 7 (20) 5 (6) # 2 (5)  
Values are presented as mean ± standard deviation except for VAS pain, CRP, ESR, and 
swollen and tender joints for which median (range) is provided. BMI, body mass index; RF, 
rheumatoid factor; CRP, C-reactive protein; ESR, erythrocyte sedimentation rate; VAS visual 
analogic scale; DAS, disease activity score; MTX, methotrexate; bDMARD, biological 
disease modifying anti-rheumatic drug. * P<0.05 for difference between sexes. ** P<0.01 for 
difference between sexes. # P<0.05 for difference between cohorts. 
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Table 3. Use of bDMARDs in the 2013 and 2015 cohorts. 
 Cohort 2013 (n=52) Cohort 2015 (n=54) Change, % 
Adalimumab 23 (44) 10 (19) -58 
Certolizumab 2 (4) 1 (2) -50 
Etanercept 19 (37) 15 (28) -24 
Golimumab 5 (10) 22 (41) +324 
Infliximab - 2 (4)  
Abatacept 2 (4) 1 (2) -50 
Rituximab 1 (2) -  
Tocilizumab - 3 (6)  
n (%).  
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Table 4. Characteristics and disease outcome parameters of patients with seronegative and 
seropositive juvenile idiopathic arthritis (JIA). 
 Seronegative, 
n=197 
Seropositive, 
n=17 
Females, n (%) 131 (66%) 17  (100)* 
BMI, kg/m2 22.1±4.3 21.3±2.6 
Age at diagnosis, years 10 (1-16) 13 (2-15)* 
ANA positive, n (%) 55 (33) 3 (20) 
HLAB27 positive, n (%) 106 (60) 2 (17) 
History of uveitis, n (%) 52 (26) 2 (13) 
HAQ 0 (0-1.5) 0 (0-0.1) 
DAS28 1.6 (1.4-5.7) 1.4 (1.4-2.6) 
VAS pain, mm 10 (0-90) 5 (0-6) 
CRP, mg/l 1 (1-100) 1 (1-8) 
ESR, mm/h 5 (0-57) 5 (2-23) 
MTX, n (%) 150 (69) 15 (88) 
bDMARD, n (%) 86 (43) 11 (65) 
no DMARD, n (%) 34 (17) 0 (0) 
Cortisone, n (%) 6 (3) 0 (0) 
   
Values are presented as median (range) except for mean ± standard deviation for BMI (body mass 
index) unless otherwise stated. ANA, anti-nuclear antibodies; HAQ, health assessment 
questionnaire; DAS28, disease activity score 28; VAS visual analogic scale; CRP, C-reactive protein; 
ESR, erythrocyte sedimentation rate; MTX, methotrexate; bDMARD, biological disease modifying 
anti-rheumatic drug. *P<0.05 from RF negative. 
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  Table 5. Longitudinal data of 23 patients who appear in both cohorts 
 2013 2015 
Time since transfer, months 6 (2-20) 36 (26-54) 
DAS28 1.5 (1.4-5.0) 1.5 (1.4-3.7) 
VAS pain, mm 9 (0-88) 10 (0-90) 
CRP,  1 (1-83) 1 (1-22) 
ESR, mm/h 9 (2-34) 7 (2-35) 
Swollen joints 0 (0-6) 0 (0-6) 
Tender joints 0 (0-3) 0 (0-4) 
bDMARDs, % 65 56 
s/bDMARDs, % 87 83 
Methotrexate, % 56 52 
Peroral cortisone, % 13 0 
Intra-articular cortisone, % 22 17 
 
Values are presented as median (range) unless otherwise stated. DAS28, disease activity score 
28; VAS, visual analog scale; CRP, C-reactive protein; ESR, erythrocyte sedimentation rate; 
bDMARDs, biologic disease-modifying antirheumatic drugs; s/bDMARDs, synthetic or 
biologic disease-modifying antirheumatic drugs. 
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